Cargando…
Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine
Anti-SARS-CoV-2 antibodies of 444 vaccinated hospital employees in Japan were measured 94–109 days and 199–212 days after receiving the second BNT162b2 vaccine dose to evaluate the intensity and duration of antibody response in our own cohort. Among uninfected participants, anti-S antibody levels we...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879303/ https://www.ncbi.nlm.nih.gov/pubmed/35214636 http://dx.doi.org/10.3390/vaccines10020177 |
_version_ | 1784658866745638912 |
---|---|
author | Matsunaga, Hidenori Takeuchi, Hidefumi Oba, Yuichiro Fujimi, Satoshi Honda, Tomoyuki Tomonaga, Keizo |
author_facet | Matsunaga, Hidenori Takeuchi, Hidefumi Oba, Yuichiro Fujimi, Satoshi Honda, Tomoyuki Tomonaga, Keizo |
author_sort | Matsunaga, Hidenori |
collection | PubMed |
description | Anti-SARS-CoV-2 antibodies of 444 vaccinated hospital employees in Japan were measured 94–109 days and 199–212 days after receiving the second BNT162b2 vaccine dose to evaluate the intensity and duration of antibody response in our own cohort. Among uninfected participants, anti-S antibody levels were greatly decreased 199–212 days after the second vaccination compared to the levels measured 94–109 days after the second vaccination (median levels: 830 AU/mL and 2425 AU/mL, respectively; p < 0.001). The rate of decrease between the two testing periods was lower in infected participants than in uninfected participants (median: 47.7% and 33.9%, respectively; p < 0.001). Anti-S antibody levels were significantly higher in females (median: females, 2546 AU/mL; males, 2041 AU/mL; p = 0.002 during the first test period). The peak body temperature after vaccination was higher in females than in males (median: females, 37.4 °C; males: 37.1 °C; p = 0.044). Older males tended to have lower antibody levels. In conclusion, the duration of the anti-S antibody response to the BNT162b2 vaccine was short-lived, particularly in males. Anti-S antibody levels of 1000 AU/mL or lower according to SARS-CoV-2 IgG II Quant (Abbott) might indicate insufficient prevention against the delta variant, and the majority of participants appeared to have lost their protection 200 days after vaccination. |
format | Online Article Text |
id | pubmed-8879303 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88793032022-02-26 Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine Matsunaga, Hidenori Takeuchi, Hidefumi Oba, Yuichiro Fujimi, Satoshi Honda, Tomoyuki Tomonaga, Keizo Vaccines (Basel) Article Anti-SARS-CoV-2 antibodies of 444 vaccinated hospital employees in Japan were measured 94–109 days and 199–212 days after receiving the second BNT162b2 vaccine dose to evaluate the intensity and duration of antibody response in our own cohort. Among uninfected participants, anti-S antibody levels were greatly decreased 199–212 days after the second vaccination compared to the levels measured 94–109 days after the second vaccination (median levels: 830 AU/mL and 2425 AU/mL, respectively; p < 0.001). The rate of decrease between the two testing periods was lower in infected participants than in uninfected participants (median: 47.7% and 33.9%, respectively; p < 0.001). Anti-S antibody levels were significantly higher in females (median: females, 2546 AU/mL; males, 2041 AU/mL; p = 0.002 during the first test period). The peak body temperature after vaccination was higher in females than in males (median: females, 37.4 °C; males: 37.1 °C; p = 0.044). Older males tended to have lower antibody levels. In conclusion, the duration of the anti-S antibody response to the BNT162b2 vaccine was short-lived, particularly in males. Anti-S antibody levels of 1000 AU/mL or lower according to SARS-CoV-2 IgG II Quant (Abbott) might indicate insufficient prevention against the delta variant, and the majority of participants appeared to have lost their protection 200 days after vaccination. MDPI 2022-01-24 /pmc/articles/PMC8879303/ /pubmed/35214636 http://dx.doi.org/10.3390/vaccines10020177 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Matsunaga, Hidenori Takeuchi, Hidefumi Oba, Yuichiro Fujimi, Satoshi Honda, Tomoyuki Tomonaga, Keizo Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine |
title | Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine |
title_full | Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine |
title_fullStr | Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine |
title_full_unstemmed | Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine |
title_short | Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine |
title_sort | waning of anti-sars-cov-2 spike antibody levels 100 to 200 days after the second dose of the bnt162b2 vaccine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879303/ https://www.ncbi.nlm.nih.gov/pubmed/35214636 http://dx.doi.org/10.3390/vaccines10020177 |
work_keys_str_mv | AT matsunagahidenori waningofantisarscov2spikeantibodylevels100to200daysaftertheseconddoseofthebnt162b2vaccine AT takeuchihidefumi waningofantisarscov2spikeantibodylevels100to200daysaftertheseconddoseofthebnt162b2vaccine AT obayuichiro waningofantisarscov2spikeantibodylevels100to200daysaftertheseconddoseofthebnt162b2vaccine AT fujimisatoshi waningofantisarscov2spikeantibodylevels100to200daysaftertheseconddoseofthebnt162b2vaccine AT hondatomoyuki waningofantisarscov2spikeantibodylevels100to200daysaftertheseconddoseofthebnt162b2vaccine AT tomonagakeizo waningofantisarscov2spikeantibodylevels100to200daysaftertheseconddoseofthebnt162b2vaccine |